// App-Quantinova.ai

2645 : BAY 1436032: A highly selective, potent and orally available inhibitor of mutant forms of IDH1

Researchers

Presenter

  • Olaf Panknin

Principal Investigators

  • Stefan Pusch

  • Lena Herbst

  • Stefan Kaulfuss

  • Katja Zimmermann

  • Hartmut Rehwinkel

  • Roland Neuhaus

  • Sven Ring

  • Michael Bruning

  • Claudia Stark

  • Katja Prelle

  • Martin Michels

  • Michael Jeffers

  • Holger Hess-Stumpp

  • Karl Ziegelbauer

  • Michael Brands

  • Alwin Kramer

  • Andreas von Deimling

Medical Centers

  • Bayer Pharma AG, Berlin, Germany

  • German Cancer Research Centre, Heidelberg, Germany

  • Bayer Pharma AG, Berlin, Germany

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

Locations

  • United States

  • Germany

Companies

  • Bayer HealthCare Pha

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Chondrosarcoma

  • Solid malignancies

  • Gliomas

Biomarkers

  • Isocitrate dehydrogenase 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved